secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2025-03-14T23:59:59+00:00
Accession:  0000950170-25-039520
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon appoints Adam Levy as CFO; Rasmus Holm-Jorgensen steps down effective April 1, 2025
--------------------------------------------------------------------------------

- Rasmus Holm-Jorgensen resigns as CFO effective April 1, 2025, for personal reasons to pursue Europe-based opportunity; no disagreement.
- Adam Levy, current SVP Corporate Affairs & Investor Relations, appointed CFO effective April 1, 2025.
- Levy's annual base salary set at $490,000, bonus target 40%, plus 35,209 stock options vesting over 4 years.
- Levy has over 25 years biopharma finance/IR experience, previously at Gilead, Turning Point Therapeutics, Zentalis.
- Levy required to relocate to Boston area within 9 months; up to $50,000 relocation reimbursement with 24-month clawback.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000095017025039520/0000950170-25-039520-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000095017025039520/acrv-20250311.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-039520

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer